Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A rare post-mortem brain study from Penn Medicine found that regions cleared of amyloid plaques had dramatically less tau buildup than neighboring untreated areas — offering some of the strongest human evidence yet that anti-amyloid therapies may slow Alzheimer's progression. The findings, published in JAMA, suggest that earlier treatment could yield even greater protective benefits.
A rare and unusually detailed examination of a donated Alzheimer's patient's brain has given researchers a striking side-by-side look at what happens when amyloid plaques are — and aren't — cleared. Brain regions where amyloid was successfully removed showed little to no tau tangle buildup, while neighboring areas that retained amyloid had significantly more tau, inflammation, and neurodegeneration. The findings, presented at the 2026 Alzheimer's Association International Conference and published in JAMA, offer some of the clearest human evidence to date that anti-amyloid therapies may limit downstream brain damage.
The patient, a man diagnosed with mild cognitive impairment in his fifties, received 30 doses of aducanumab over 4.5 years in a clinical trial. After his death — more than a decade after his first symptoms — his donated brain showed a "Goldilocks" patchwork: raised brain ridges (gyri) largely cleared of amyloid with minimal tau, while the grooves between them (sulci) still harbored plaques and showed far more damage.
Key Takeaways:
Why it matters: This case provides rare, direct human evidence that removing amyloid doesn't just address one hallmark of Alzheimer's — it may interrupt a chain reaction that leads to broader brain damage. For clinicians and researchers, it strengthens the case for early intervention and longer-term outcome tracking in Alzheimer's trials.
